Evaluation of P-wave dispersion in patients with newly diagnosed coronavirus disease 2019


Yenerçaǧ M., Arslan U., Şeker O. O., Dereli S., Kaya A., Doǧduş M., ...Daha Fazla

Journal of Cardiovascular Medicine, cilt.22, sa.3, ss.197-203, 2021 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2459/jcm.0000000000001135
  • Dergi Adı: Journal of Cardiovascular Medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.197-203
  • Anahtar Kelimeler: atrial fibrillation, coronavirus disease 2019, P-wave dispersion, severe acute respiratory syndrome-coronavirus-2
  • Uşak Üniversitesi Adresli: Evet

Özet

AimThe aim of the current study was to evaluate P-wave dispersion (PWD) as a predictor of atrial fibrillation in patients with newly diagnosed COVID-19. In addition, the relationship between the PWD and inflammation parameters was investigated.MethodsA total of 140 newly diagnosed COVID-19 patients and 140 age- and sex-matched healthy individuals were included in the study. The risk of atrial fibrillation was evaluated by calculating the electrocardiographic PWD. C-reactive protein (CRP), white blood cell, neutrophil and neutrophil-to-lymphocyte ratio (NLR) were measured in patients with newly diagnosed COVID-19.ResultsPWD, white blood cell, NLR and CRP levels were significantly higher in the COVID-19 group than the control group. There was a significant positive correlation between PWD and CRP level (rs = 0.510, P < 0.001) and NLR in COVID-19 group (rs = 0.302, P = 0.001). In their follow-up, 13 (9.3%) patients, 11 of whom were in the ICU, developed new atrial fibrillation.ConclusionOur study showed for the first time in literature that the PWD, evaluated electrocardiographically in patients with newly diagnosed COVID-19, was prolonged compared with normal healthy individuals. A positive correlation was found between PWD, CRP level and NLR. We believe that pretreatment evaluation of PWD in patients with newly diagnosed COVID-19 would be beneficial for predicting atrial fibrillation risk.